Sanofi, AstraZeneca clinch first OK for RSV antibody — just as vaccines line up at regulators

The EU has officially stamped its seal of approval for nirsevimab, the antibody jointly developed by Sanofi and AstraZeneca to prevent RSV disease in infants.

Beyfortus will be the first single-dose protective option for newborns and infants during their first RSV season, the companies noted. While a different antibody, Synagis, has been on the market for two decades, it only covers a subset of infants at high risk of severe disease and it has to be administered monthly.